SecBot SecBot
PRESS-RELEASE ·Filed Apr 21, 2026

OLMA

Olema Oncology
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

Monitor the ASCO poster presentation on May 30 for early signs of safety, tolerability, and anti-tumor activity of OP-3136, which could de-risk the asset and provide a near-term catalyst for re-rating. Absent efficacy signals, sentiment may remain muted despite the event.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$16.24
T+0 close · Apr 21, 2026 · via day close
Latest settled
−29.37%
T+60 · $11.47
Vs SPY
−34.15%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 22 $16.24entry
  2. T+1 · 7mo ago −5.48%α −5.09% · $15.35
  3. T+5 · 7mo ago −12.32%α −12.37% · $14.24
  4. T+20 · 6mo ago −19.34%α −22.50% · $13.10
  5. T+60 · 4mo ago −29.37%α −34.15% · $11.47
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Olema Oncology announced upcoming presentations of initial Phase 1 data for OP-3136 and a trial-in-progress overview of its Phase 3 OPERA-02 study at ASCO 2026. The data readout for OP-3136, a novel KAT6 inhibitor, represents an early clinical milestone for the pipeline beyond its lead candidate palazestrant.

Key Facts

  • Olema Oncology will present initial Phase 1 clinical data for OP-3136 at ASCO 2026 on May 30, 2026.
  • OP-3136 is a novel oral selective KAT6A/B inhibitor being studied in advanced solid tumors and ER+, HER2− breast cancer.
  • The company will also present a trial-in-progress poster for the Phase 3 OPERA-02 study of palazestrant plus ribociclib in ER+, HER2− advanced breast cancer on June 1, 2026.
  • OP-3136 received FDA IND clearance in December 2024; enrollment is ongoing in the Phase 1 study.
  • Palazestrant has FDA Fast Track designation and is in two ongoing Phase 3 trials (OPERA-01 and OPERA-02).

Financial Impact

No financial impact in near term; data readout may influence valuation based on clinical signal.

pipeline valueR&D valuationinvestor sentiment

Risk Factors

  • Early-phase data may show limited clinical activity or safety concerns, leading to negative sentiment.
  • Lack of near-term commercial catalysts for OP-3136 given its early development stage.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3278398

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 21, 2026